Author

Marc Ferrante

COMPREHENSIVE CHARACTERIZATION OF THE EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN ULCERATIVE COLITIS: RESULTS FROM THE LOVE-UC STUDY
COMPREHENSIVE CHARACTERIZATION OF THE EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN ULCERATIVE COLITIS: RESULTS FROM THE LOVE-UC STUDY

Marc Ferrante  et al.

RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 INSPIRE STUDY
RISANKIZUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: EFFICACY AND SAFETY IN THE RANDOMIZED PHASE 3 INSPIRE STUDY

Marc Ferrante  et al.

PREDICTING TOFACITINIB INDUCED ENDOSCOPIC RESPONSE IN ULCERATIVE COLITIS THROUGH A MUCOSAL BIOMARKER
PREDICTING TOFACITINIB INDUCED ENDOSCOPIC RESPONSE IN ULCERATIVE COLITIS THROUGH A MUCOSAL BIOMARKER

Marc Ferrante  et al.

EFFICACY OF UPADACITINIB FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE BY DISEASE DURATION: A POST HOC ANALYSIS OF PHASE 3 INDUCTION AND MAINTENANCE STUDIES
EFFICACY OF UPADACITINIB FOR MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE BY DISEASE DURATION: A POST HOC ANALYSIS OF PHASE 3 INDUCTION AND MAINTENANCE STUDIES

Marc Ferrante  et al.

INTESTINAL EXPRESSION OF THE SARS-COV-2 RECEPTOR ACE2 AND TMPRSS2 IN BIOPSIES AND DERIVED ORGANOIDS FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE
INTESTINAL EXPRESSION OF THE SARS-COV-2 RECEPTOR ACE2 AND TMPRSS2 IN BIOPSIES AND DERIVED ORGANOIDS FROM PATIENTS WITH INFLAMMATORY BOWEL DISEASE

Marc Ferrante  et al.

EXPOSURE TO AN INFLAMMATORY MIX RE-INDUCES INFLAMMATION IN ORGANOIDS OF ULCERATIVE COLITIS PATIENTS, INDEPENDENT OF THE INFLAMMATORY STATE OF THE TISSUE OF ORIGIN
EXPOSURE TO AN INFLAMMATORY MIX RE-INDUCES INFLAMMATION IN ORGANOIDS OF ULCERATIVE COLITIS PATIENTS, INDEPENDENT OF THE INFLAMMATORY STATE OF THE TISSUE OF ORIGIN

Marc Ferrante  et al.

European evidence based consensus on surgery for ulcerative colitis
European evidence based consensus on surgery for ulcerative colitis

Marc Ferrante  et al.

RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY
RISANKIZUMAB VERSUS USTEKINUMAB FOR PATIENTS WITH MODERATE TO SEVERE CROHN'S DISEASE: RESULTS FROM THE PHASE 3B SEQUENCE STUDY

Marc Ferrante  et al.

ENDOSCOPIC AND HISTOLOGIC REMISSION IN TOFACITINIB TREATED REFRACTORY MODERATE-TO-SEVERE PATIENTS WITH ULCERATIVE COLITIS: A PROSPECTIVE REAL-LIFE COHORT
ENDOSCOPIC AND HISTOLOGIC REMISSION IN TOFACITINIB TREATED REFRACTORY MODERATE-TO-SEVERE PATIENTS WITH ULCERATIVE COLITIS: A PROSPECTIVE REAL-LIFE COHORT

Marc Ferrante  et al.

PATIENT REPORTED OUTCOME SEVERITY DOES NOT IMPACT ENDOSCOPIC HEALING IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF SONIC
PATIENT REPORTED OUTCOME SEVERITY DOES NOT IMPACT ENDOSCOPIC HEALING IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF SONIC

Marc Ferrante  et al.

MICROBIOME DYSBIOSIS, INTESTINAL EPITHELIAL CELL DYSFUNCTION AND IMMUNE SYSTEM DEREGULATION IN PATIENTS WITH CROHN'S DISEASE
MICROBIOME DYSBIOSIS, INTESTINAL EPITHELIAL CELL DYSFUNCTION AND IMMUNE SYSTEM DEREGULATION IN PATIENTS WITH CROHN'S DISEASE

Marc Ferrante  et al.

MUCOSAL HEALING WITH VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM EARNEST, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN CHRONIC POUCHITIS
MUCOSAL HEALING WITH VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: EVIDENCE FROM EARNEST, A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL IN CHRONIC POUCHITIS

Marc Ferrante  et al.

AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES
AN ADDITIONAL 12 WEEKS OF RISANKIZUMAB THERAPY INDUCES CLINICAL RESPONSE IN PATIENTS WITH MODERATE TO SEVERE CROHN’S DISEASE WHO FAILED TO ACHIEVE CLINICAL RESPONSE AFTER AN INITIAL INDUCTION PERIOD: 24-WEEK POOLED ANALYSIS OF TWO PHASE 3 STUDIES

Marc Ferrante  et al.

DISEASE ACCEPTANCE, BUT NOT PERCEIVED CONTROL, IS UNIQUELY ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE-RELATED DISABILITY
DISEASE ACCEPTANCE, BUT NOT PERCEIVED CONTROL, IS UNIQUELY ASSOCIATED WITH INFLAMMATORY BOWEL DISEASE-RELATED DISABILITY

Marc Ferrante  et al.

EFFECTIVENESS OF USTEKINUMAB AS INDUCTION THERAPY FOR CHRONIC ANTIBIOTIC REFRACTORY POUCHITIS
EFFECTIVENESS OF USTEKINUMAB AS INDUCTION THERAPY FOR CHRONIC ANTIBIOTIC REFRACTORY POUCHITIS

Marc Ferrante  et al.

LONG-TERM RISK OF DELAYED POSTOPERATIVE CROHN’S DISEASE RECURRENCE IN PATIENTS WITH NO OR MILD RECURRENCE AT FIRST ENDOSCOPIC ASSESSMENT
LONG-TERM RISK OF DELAYED POSTOPERATIVE CROHN’S DISEASE RECURRENCE IN PATIENTS WITH NO OR MILD RECURRENCE AT FIRST ENDOSCOPIC ASSESSMENT

Marc Ferrante  et al.

SCORING OF HISTOLOGICAL REMISSION IN ULCERATIVE COLITIS BASED ON AUTOMATED COMPUTER-AIDED ANALYSIS OF ENDOSCOPIC IMAGES OUTPERFORMS HUMAN SCORING
SCORING OF HISTOLOGICAL REMISSION IN ULCERATIVE COLITIS BASED ON AUTOMATED COMPUTER-AIDED ANALYSIS OF ENDOSCOPIC IMAGES OUTPERFORMS HUMAN SCORING

Marc Ferrante  et al.

COVID19 VACCINATION COVERAGE IN FLEMISH PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES
COVID19 VACCINATION COVERAGE IN FLEMISH PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES

Marc Ferrante  et al.

CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY
CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY

Marc Ferrante  et al.

COMPARISON OF THE RISK OF CROHN'S DISEASE POSTOPERATIVE RECURRENCE BETWEEN MODIFIED RUTGEERTS SCORE I2A AND I2B CATEGORIES: AN INDIVIDUAL PATIENT DATA META-ANALYSIS
COMPARISON OF THE RISK OF CROHN'S DISEASE POSTOPERATIVE RECURRENCE BETWEEN MODIFIED RUTGEERTS SCORE I2A AND I2B CATEGORIES: AN INDIVIDUAL PATIENT DATA META-ANALYSIS

Marc Ferrante  et al.

Item 21 - 40 / 42
1
2
3